← Back to all trials
Recruiting
NCT07811063
A Study to Test a Single Dose of a New Tablet Formulation of TRTL-729
Conditions: Healthy Volunteers
Sex: All
Ages: 18 Years – 55 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 10
Sponsor: Tortugas Neuroscience, Inc.
Location: Clinical Trial Site Auckland
Summary
This study assesses the safety, tolerability, and pharmacokinetics (PK) of the tablet formulation of TRTL-729 in healthy adults.
Eligibility Criteria
Inclusion Criteria:
1. Generally healthy, ambulatory male or female adults aged 18 to 55 years, as determined by the investigator.
2. Able and willing to provide written informed consent and comply with all study procedures and the visit schedule.
3. Body Mass Index (BMI) 18.0 to 32.0 kilograms per meter square kg/m\^2 and body weight greater than (\>)50 kilograms (kg).
4. Clinically acceptable medical history, physical examination, vital signs, clinical laboratory tests, and 12-lead electrocardiogram (ECG), as determined by the investigator.
5. QT interval Corrected using Fridericia's Formula (QTcF) lesser than or equal to (≤)450 milliseconds (msec) for males or ≤470 msec for females.
6. Nonsmokers or light smokers (less than \[\
Source: ClinicalTrials.gov (NCT07811063). StuddyBuddy aggregates publicly available trial information.
